H Valantine
Overview
Explore the profile of H Valantine including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
259
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Farrero Torres M, Pando M, Luo C, Luikart H, Valantine H, Khush K
Clin Transplant
. 2017 Sep;
31(11).
PMID: 28940521
Background: The development of donor-specific antibodies (DSA) to human leukocyte antigens (HLA) has been associated with acute rejection and allograft failure after heart transplantation. Not all DSA, however, can fix...
2.
Vrtovec B, Haddad F, Pham M, Deuse T, Fearon W, Schrepfer S, et al.
Transplant Proc
. 2013 Aug;
45(6):2406-9.
PMID: 23953556
Background: We evaluated the potential effects of granulocyte colony-simulating factor (G- CSF) on the incidence of rejection and allograft vasculopathy in heart transplant recipients. Methods: Of 247 patients undergoing heart...
3.
Epailly E, Albanell J, Andreassen A, Bara C, Campistol J, Delgado J, et al.
Clin Transplant
. 2011 May;
25(5):E475-86.
PMID: 21592231
Although malignancy is a major threat to long-term survival of heart transplant (HT) recipients, clear strategies to manage immunosuppression in these patients are lacking. Several lines of evidences support the...
4.
Deuse T, Haddad F, Pham M, Hunt S, Valantine H, Bates M, et al.
Am J Transplant
. 2008 Jun;
8(9):1769-74.
PMID: 18557718
Human heart transplantation started 40 years ago. Medical records of all cardiac transplants performed at Stanford were reviewed. A total of 1446 heart transplantations have been performed between January 1968...
5.
Chapman J, Valantine H, Albanell J, Arns W, Campistol J, Eisen H, et al.
Transplant Proc
. 2007 Dec;
39(10):2937-50.
PMID: 18089298
While advances in immunosuppressive therapy have allowed dramatic improvements in the control of acute allograft rejection, there is still a need to improve long-term graft and patient survival rates following...
6.
Lehmkuhl H, Ross H, Eisen H, Valantine H
Transplant Proc
. 2006 Jan;
37(10):4145-9.
PMID: 16387066
The proliferation signal inhibitor everolimus is efficacious for reducing the incidence of acute rejection and cardiac allograft vasculopathy (CAV) in heart transplantation; and it has the potential to facilitate cyclosporine...
7.
Eisen H, Kobashigawa J, Starling R, Valantine H, Mancini D
Transplant Proc
. 2005 Apr;
37(4 Suppl):4S-17S.
PMID: 15809102
Graft failure and mortality among heart transplant recipients remains higher than in populations receiving renal transplants. A major cause of graft loss is cardiac allograft vasculopathy (CAV), a condition characterized...
8.
MOORE R, Hernandez D, Valantine H
Drug Saf
. 2001 Oct;
24(10):755-66.
PMID: 11676303
Cardiovascular disease is now the leading cause of death in transplant recipients. This is due, in part, to the vulnerability of these patients to a complicated set of conditions including...
9.
Keeffe B, Valantine H, Keeffe E
Liver Transpl
. 2001 Sep;
7(9):755-61.
PMID: 11552207
Patients with end-stage liver disease and coronary artery disease (CAD) being considered for orthotopic liver transplantation (OLT) present a difficult dilemma. The availability of multiple screening tests and newer treatment...
10.
Valantine H, Rickenbacker P, Kemna M, Hunt S, Chen Y, Reaven G, et al.
Circulation
. 2001 May;
103(17):2144-52.
PMID: 11331254
Background: This study examines the hypothesis that metabolic abnormalities of dysmetabolic syndrome are risk factors for transplant coronary artery disease (TxCAD). Methods And Results: Sixty-six patients without overt diabetes, 2...